For USA healthcare professionals only. Spotlighting a GSK-sponsored Innovation Theatre session that took place on the 14th November 2023 at the American College of Rheumatology (ACR) Convergence, held in San Diego, California, USA, this review article summarises expert insights into opportunistic infections, and the need for holistic management strategies in immunocompromised patients, secondary to rheumatologic conditions and their treatment.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles
6 Mins
12th
May
Preparing for the Next Outbreak: Interview with Maria Zambon
The UK Health Security Agency (UKHSA) is an executive government agency, sponsored by the Department of Health and Social…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

7 Mins
9th
May
Lessons from Respiratory Viruses: Interview with Peter Openshaw
Peter Openshaw | Proconsul, Professor of Experimental Medicine, National Heart & Lung Institute – Faculty of Medicine, Imperial…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

4 Mins
24th
March
Unravelling Clinical AI: Interview with Nicholas Fuggle
EMJ is delighted to introduce Nicholas Fuggle, Associate Professor in Rheumatology at the University of Southampton, UK, and co-organiser…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

6 Mins
20th
March
Evaluation of Antimicrobial Resistance Patterns in Afghanistan
Existing studies reveal alarming levels of AMR in Afghanistan, driven by factors such as self-medication, overuse of antibiotics, and inadequate awareness…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.